

Alexandria Moseley



tel: [REDACTED]

3 December 2007

Christopher Feinmann  
Project director, Health Technology Appraisal for CSII  
NICE  
Via email

Re: Patient Expert comments on the Appraisal Consultation Document for Continuous Subcutaneous Insulin Infusion

Dear Mr Feinmann-

Thank you for inviting my comments on the ACD. On the whole, I agree with the Committee's Preliminary recommendations.

- i) I believe that the committee considered all relevant evidence.
- ii) I think it was observed at the meeting that the cost effectiveness models are not applicable to paediatric use of CSII, as addressed in Section 4.3.7. I feel that the implications and resource impact on the NHS for paediatric use are inaccurate. However, the preliminary views are appropriate.
- iii) I believe that the provisional recommendations are sound and suitable. The criteria for MDI failure is a welcome addition. Section 1.5 might benefit from more concrete parameters for continuation of CSII. I agree with Dr. Peter Winocour's suggestion in his response to the assessment report, that success of pump therapy might be better defined as a reduction of 1% in HbA1c and severe hypos reduced by 50% over a one year period.
- iv) I see no equality related issues.

I greatly appreciate the opportunity to have participated in this process and look forward to seeing the final outcome.

Sincerely,

Alexandria Moseley